Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SYNCAR-001 |
Trade Name | |
Synonyms | SYNCAR 001|SYNCAR001 |
Drug Descriptions |
SYNCAR-001 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 as well as a mutated IL-2 receptor beta, which have potential antitumor activity (Cancer Res (2021) 81 (13_Supplement): 1512). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
STK-009 + SYNCAR-001 | STK-009 SYNCAR-001 | 0 | 1 |
SYNCAR-001 | SYNCAR-001 | 0 | 0 |